Cleveland, OH – According to filings with the U.S. Securities and Exchange Commission, Trailhead Biosystems is raising $8,575,741.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Jan Jensen played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Trailhead Biosystems

Trailhead Biosystems merges developmental biology and cell therapeutics with cutting edge hardware, and computerized experimental design and analysis to perform process-specific parameter optimization for customers seeking to develop cell therapies. Implementing Quality by Design (QbD) principles, cell culture optimization is done by utilizing Design of Experiment (DoE) theory combined with Multivariate Data Analysis (MVDA). This allows Trailhead to generate mathematical models of the biological system, understand the effector-response relationship in cell culture, and provide a systems biology analysis of the differentiation space. DoE-based experimental design and robotic execution greatly reduce the number of experiments and time needed for optimizing a large number of variables simultaneously.

To learn more about Trailhead Biosystems, visit http://www.trailbiosystems.com/

Contact:
Jan Jensen, Chief Executive Officer
216-445-3835
https://www.linkedin.com/in/janjensen1/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved